1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030

Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030

  • September 2020
  • 100 pages
  • ID: 5962309
  • Format: PDF
  • Delve Insight
Up to $2250 off Until Nov 30th 2020

Summary

Table of Contents

‘Pemphigus Vulgaris (PV)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Pemphigus Vulgaris (PV) Disease Understanding
Pemphigus Vulgaris (PV) is defined as a potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters, and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.
PV is subdivided into two subtypes: mucosal-dominant type and mucocutaneous type. The mucosal-dominant type of PV shows blisters mainly and erosive lesions on the oral mucosa while mucocutaneous type also shows flaccid bullae and intractable erosions of the skin. PV is further segmented based on the severity of the disease as mild, moderate and severe.
Pemphigus Vulgaris (PV) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Pemphigus Vulgaris (PV) Detailed Epidemiology Segmentation
• The increasing geriatric population and rising prevalence of PV generates a large patient population in the 7MM. In 2017, the diagnosed prevalent population of PV in the 7MM was 41,217.
• The United States contributes the largest share with 13,526 cases in 2017 acquiring near about 32.81% of the totals 7MM share. On the other hand, EU5 and Japan account for 60.10% and 7.09% diagnosed prevalent population share respectively in 2017.
• A female predominance in PV is well established. However, the genetic and physiological basis for this gender bias is not well understood. In 2017, males and females contribute to 5,275 and 8,251 diagnosed prevalent cases in the US.
• Epidemiology model for PV estimates that out of the total diagnosed prevalent population of 13,526 cases in the US for PV in 2017, 5,814 cases are of mild, 3,678 cases are of moderate, and 4,034 accounted for severe cases, respectively.
• The majority of the PV cases were found in adults between 60–70 years of age. In 2017, 3,014 cases, 2,449 cases, were contributed by patients age 60–69 years, 70–79 years, and lowest cases observed in the age-group of 0–17 years (406 cases) in 2017, respectively in the US.

Scope of the Report
• The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of PV.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV.

Report Highlights
• 11-Year Forecast of PV
• 7MM Coverage
• Total Diagnosed Prevalent Population of PV
• Gender-specific Diagnosed Prevalent Population of PV
• Severity-specific Diagnosed Prevalent Population of PV
• Age-specific Diagnosed Prevalent Population of PV

Key Questions Answered
• What is the disease risk, burden and unmet needs of PV?
• What is the historical PV patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of PV at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
• Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The PV report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM PV epidemiology forecast.
• The PV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The PV epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($3750)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy, and Geography

  • $ 4500
  • September 2020
  • 76 pages

The Netherton syndrome market was valued at US$ 19.57 million in 2019 and is projected to reach US$ 74.31 million by 2027; it is expected to grow at a CAGR of 20.3%during 2020–2027. The growth of the ...

  • World
  • United States
  • Therapy
  • Epidemiology
  • Industry analysis
  • Drug Approval
  • Final Consumption Expenditures

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on